New drug cocktail aims to boost transplant success in elderly leukemia patients

NCT ID NCT07563920

Not yet recruiting Disease control Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a combination of three chemotherapy drugs (thiotepa, busulfan, and fludarabine) given before a stem cell transplant can help older adults with acute myeloid leukemia stay in remission longer. About 93 patients aged 55 to 75 who are in their first remission will receive the treatment and be followed for at least a year. The goal is to see if this approach reduces relapse and improves survival, while managing side effects like graft-versus-host disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: thiotepa, busulfan, and fludarabine (TBF) chemotherapy
What this could lead to: If successful, this approach could offer elderly AML patients a better chance at long-term disease control after a stem cell transplant from a partially matched donor.
What could go wrong: This is a small, early-stage study at one center, so results may not apply broadly. The chemotherapy and transplant carry serious risks like infection, graft-versus-host disease, and organ damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA

More trials for these conditions

Other studies related to the condition(s) this trial covers.